Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals (Detail) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Oct. 01, 2017	Oct. 02, 2016	Oct. 01, 2017	Oct. 02, 2016
Restructuring Reserve [Roll Forward]
Balance, December 31, 2016	[1]			$ 1,583
Provision	[2]	$ 91	$ 404	150	$ 574
Utilization and other	[3]			(551)
Balance, October 1, 2017	[4]	1,182		1,182
Employee Termination Costs [Member]
Restructuring Reserve [Roll Forward]
Balance, December 31, 2016	[1]			1,547
Provision				9
Utilization and other	[3]			(401)
Balance, October 1, 2017	[4]	1,154		1,154
Asset Impairment Charges [Member]
Restructuring Reserve [Roll Forward]
Balance, December 31, 2016	[1]			0
Provision				126
Utilization and other	[3]			(126)
Balance, October 1, 2017	[4]	0		0
Exit Costs [Member]
Restructuring Reserve [Roll Forward]
Balance, December 31, 2016	[1]			36
Provision				16
Utilization and other	[3]			(24)
Balance, October 1, 2017	[4]	$ 28		$ 28

[1] Included in Other current liabilities ($863 million) and Other noncurrent liabilities ($720 million).

[2] In the third quarter and first nine months of 2017, restructuring charges are primarily associated with our acquisitions of Hospira and Medivation, as well as cost-reduction and productivity initiatives not associated with acquisitions. In the third quarter and first nine months of 2016, restructuring charges are largely associated with cost-reduction and productivity initiatives not associated with acquisitions, as well as our acquisitions of Hospira and Medivation. In the third quarter and first nine months ended October 1, 2017, Employee terminations primarily include revisions of our estimates of severance benefits. Employee termination costs are generally recorded when the actions are probable and estimable and include accrued severance benefits, pension and postretirement benefits, many of which may be paid out during periods after termination. The restructuring activities for 2017 are associated with the following: • For the third quarter of 2017, IH ($4 million); EH ($1 million); WRD/GPD ($15 million); manufacturing operations ($47 million); and Corporate ($25 million). • For the first nine months of 2017, IH ($10 million); EH ($9 million income); WRD/GPD ($29 million); manufacturing operations ($70 million); and Corporate ($51 million). The restructuring activities for 2016 are associated with the following: • For the third quarter of 2016, IH ($148 million); EH ($28 million); WRD/GPD ($52 million); manufacturing operations ($108 million); and Corporate ($67 million). • For the first nine months of 2016, IH ($162 million); EH ($19 million); WRD/GPD ($104 million); manufacturing operations ($181 million); and Corporate ($107 million).

[3] Includes adjustments for foreign currency translation.

[4] Included in Other current liabilities ($533 million) and Other noncurrent liabilities ($650 million).